STENTYS announced that the Board of Directors has appointed Christophe Lottin as the new Chief Executive Officer of the company. Gonzague Issenmann has organized his succession and will ensure a smooth transition over the next quarter. Christophe Lottin, who has twenty years of experience in cardiology, rose through the sales organization of Boston Scientific and Hexacath France, up to the position of President with responsibility for Benelux, Switzerland and Canada. In particular, he was instrumental in the commercial success of the Optimax coronary stent. In his multiple roles, he had to coordinate the critical departments of a stent company, such as R&D, Clinical and Regulatory affairs.